Neville Rodie & Shaw’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Neville Rodie & Shaw’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,830	Closed	-$519K	–	263
2021 Q2	$519K	Sell	3,830 -1,750	-31%	-$230K	0.04%	178
2021 Q1	$757K	Hold	5,580	–	–	0.06%	148
2020 Q4	$786K	Hold	5,580	–	–	0.07%	136
2020 Q3	$622K	Buy	5,580 +2,750	+97%	+$308K	0.06%	144
2020 Q2	$317K	Buy	+2,830	New	+$279K	0.03%	186
2019 Q2	–	Sell	-2,375	Closed	-$215K	–	253
2019 Q1	$215K	Buy	+2,375	New	+$202K	0.02%	234

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Neville Rodie & Shaw's XBI Position: Q3 2021 in Review

Neville Rodie & Shaw sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2021, closing a stake of 3,830 shares — an estimated $519K sold.

Neville Rodie & Shaw first reported a position in XBI in Q1 2019 and held it in 6 quarters. The position peaked at $786K in Q4 2020. 635 funds tracked by Wall St. Rank hold XBI as of Q3 2021.

Neville Rodie & Shaw reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2021 after selling out during the quarter.
Neville Rodie & Shaw sold 3,830 State Street SPDR S&P Biotech ETF shares in Q3 2021, an estimated $519K.
Neville Rodie & Shaw first reported a position in State Street SPDR S&P Biotech ETF in Q1 2019 and held it in 6 quarters.
Neville Rodie & Shaw's State Street SPDR S&P Biotech ETF position peaked at $786K in Q4 2020.
635 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2021.

Based on Neville Rodie & Shaw's 13F filing for Q3 2021, filed 6 Oct 2021.